Kunimi K, Amano T, Lee S W, Fuse H, Uchibayashi T, Miyazaki K, Ohkawa M
Department of Urology, Kanazawa University, Japan.
Int Urol Nephrol. 1995;27(5):575-85. doi: 10.1007/BF02564744.
We surveyed the comparative clinical features of patients with stage A1 and stage A2 prostate cancer. Preoperatively, prostate specific antigen (PSA) level was elevated in 50.0% of stage A2 patients as compared to 18.2% of stage A1 patients. Compared to low positivity of prostatic acid phosphatase in 12.5% of stage A2 and in 0% of stage A1, PSA was more sensitive to the presence of incidental carcinoma. During the observation period (mean 35.7 months) no stage A patient died of cancer. No evidence of the disease showed significantly higher rate, and death without cancer was significantly lower in stage A1.
我们调查了A1期和A2期前列腺癌患者的比较临床特征。术前，A2期患者中50.0%的前列腺特异性抗原（PSA）水平升高，而A1期患者中这一比例为18.2%。与A2期12.5%和A1期0%的前列腺酸性磷酸酶低阳性率相比，PSA对偶然癌的存在更敏感。在观察期（平均35.7个月）内，没有A期患者死于癌症。无疾病证据的发生率在A1期显著更高，而非癌症死亡在A1期显著更低。
